Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase

Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.